BCR-ABL1 Genetic Test-Introduction, Test Result, Test Method, Clinical Significance, and Keynotes

by

Introduction

The BCR-ABL1 genetic test is a diagnostic laboratory test that plays a crucial role in the diagnosis, prognosis, and management of certain types of leukemia, most notably chronic myeloid leukemia (CML) and a subset of acute lymphoblastic leukemia (ALL). This test helps identify the presence of a specific genetic abnormality known as the BCR-ABL1 fusion gene. Here is an introduction to the BCR-ABL1 genetic test:

  1. Background:
    • Chronic myeloid leukemia (CML) and a small percentage of acute lymphoblastic leukemia (ALL) cases are associated with a genetic abnormality called the Philadelphia chromosome (Ph chromosome). This abnormality results from a translocation (exchange of genetic material) between two chromosomes, typically chromosomes 9 and 22. As a result of this translocation, a fusion gene called BCR-ABL1 is formed.
  2. BCR-ABL1 Fusion Gene:
    • The BCR-ABL1 fusion gene encodes a protein with abnormal tyrosine kinase activity. This protein, known as the BCR-ABL1 tyrosine kinase, is responsible for uncontrolled cell division and is a key driver of leukemia.
  3. Purpose of the Test:
    • The BCR-ABL1 genetic test is performed to detect the presence of the BCR-ABL1 fusion gene in a patient’s blood or bone marrow sample.
    • It is used for the diagnosis of CML and a subset of ALL and aids in distinguishing these leukemias from other similar conditions.
  4. Monitoring Disease Progression:
    • Once a diagnosis of CML or Ph-positive ALL is established, the BCR-ABL1 genetic test is used for disease monitoring.
    • Quantitative BCR-ABL1 testing measures the amount of BCR-ABL1 transcripts (mRNA) in the blood, allowing doctors to assess disease progression and response to treatment. This is often referred to as the “BCR-ABL1 transcript level” or “BCR-ABL1 molecular testing.”
  5. Treatment Decision-Making:
    • The results of BCR-ABL1 testing guide treatment decisions. The goal of therapy is often to achieve and maintain deep molecular remission, which means reducing or eliminating the BCR-ABL1 transcripts to very low or undetectable levels.
    • Tyrosine kinase inhibitors (TKIs) are the primary treatment for CML, and their selection and dosage are often based on BCR-ABL1 testing results.
  6. Methodology:
    • BCR-ABL1 genetic testing is typically performed using molecular techniques like polymerase chain reaction (PCR) or reverse transcriptase quantitative PCR (RT-qPCR). These techniques amplify and quantitate the BCR-ABL1 transcripts present in the patient’s sample.
  7. Interpretation of Results:
    • The results of BCR-ABL1 testing are reported as a percentage of BCR-ABL1 transcripts compared to a standardized reference (e.g., International Scale or IS). Lower percentages indicate a better response to treatment.
  8. Prognosis:
    • BCR-ABL1 testing is also used for prognosis determination. Patients who achieve and maintain deep molecular remission have a significantly better long-term prognosis.

Test Result, and Test Method

The results of a BCR-ABL1 genetic test provide information about the presence and quantity of the BCR-ABL1 fusion gene or its transcripts in a patient’s blood or bone marrow sample. The test methods used to obtain these results typically involve molecular techniques such as polymerase chain reaction (PCR) or reverse transcriptase quantitative PCR (RT-qPCR). Here’s a more detailed explanation of test results and methods for the BCR-ABL1 genetic test:

Test Results:

  1. Positive Result:
    • A positive result indicates the presence of the BCR-ABL1 fusion gene or its transcripts in the patient’s sample.
    • The result may be reported as a percentage or ratio of BCR-ABL1 transcripts to a standardized reference, often referred to as the “BCR-ABL1 transcript level” or “BCR-ABL1/ABL1 ratio.”
  2. Negative Result:
    • A negative result suggests that the BCR-ABL1 fusion gene or transcripts are not detectable in the patient’s sample.
    • However, a negative result does not necessarily rule out the possibility of CML or Ph-positive ALL, as the test’s sensitivity can vary. Further testing or clinical evaluation may be needed.
  3. Quantitative Result:
    • In addition to detecting the presence of BCR-ABL1 transcripts, the test provides a quantitative measurement of their abundance in the patient’s sample. This is typically reported as a percentage or ratio.
    • Lower percentages or ratios indicate a better response to treatment and a deeper molecular remission.

Test Methods:

  1. Polymerase Chain Reaction (PCR):
    • PCR is a widely used molecular biology technique that amplifies specific DNA sequences in a patient’s sample.
    • For BCR-ABL1 testing, RNA (mRNA) is first reverse-transcribed into complementary DNA (cDNA). Then, PCR is used to amplify and quantitate the BCR-ABL1 cDNA.
    • The results are reported as a percentage of BCR-ABL1 transcripts compared to a standardized reference, often expressed on the International Scale (IS).
  2. Reverse Transcriptase Quantitative PCR (RT-qPCR):
    • RT-qPCR is a variation of PCR specifically designed to quantitate RNA (mRNA) levels in a sample.
    • In BCR-ABL1 testing, RNA is reverse-transcribed into complementary DNA (cDNA), and then qPCR is used to measure the quantity of BCR-ABL1 cDNA.
    • This method is highly sensitive and is commonly used for monitoring BCR-ABL1 transcript levels in patients with CML or Ph-positive ALL.
  3. Next-Generation Sequencing (NGS):
    • NGS technologies are increasingly used in genetic testing, including BCR-ABL1 testing.
    • NGS can provide information about the specific BCR-ABL1 fusion variant present in the patient’s sample, which can be relevant for treatment decisions.
  4. Fluorescence In Situ Hybridization (FISH):
    • FISH is a cytogenetic technique used to visualize specific DNA sequences within a patient’s chromosomes.
    • While less common for quantitative BCR-ABL1 testing, FISH may be used for certain diagnostic purposes, such as detecting the Philadelphia chromosome.

The choice of test method may depend on the laboratory’s capabilities and the clinical context. Molecular methods like PCR and RT-qPCR are the most common and sensitive techniques for monitoring BCR-ABL1 transcript levels in the management of CML and Ph-positive ALL.

Clinical Significance

The BCR-ABL1 genetic test holds significant clinical importance, particularly in the diagnosis, prognosis, treatment, and monitoring of certain types of leukemia, most notably chronic myeloid leukemia (CML) and a subset of acute lymphoblastic leukemia (ALL). Here are the key clinical significances of the BCR-ABL1 genetic test:

1. Diagnosis:

  • CML Confirmation: The BCR-ABL1 test is essential for confirming the diagnosis of chronic myeloid leukemia (CML). The presence of the BCR-ABL1 fusion gene or its transcripts is a hallmark of CML. It helps distinguish CML from other similar conditions.
  • Ph-Positive ALL: In a subset of acute lymphoblastic leukemia (ALL) cases, the presence of the BCR-ABL1 fusion gene (also known as the Philadelphia chromosome) is associated with a more aggressive form of the disease. The BCR-ABL1 test is used to diagnose Ph-positive ALL.

2. Prognosis:

  • Risk Stratification: Quantitative BCR-ABL1 testing provides valuable information for risk stratification and prognosis. Patients with higher BCR-ABL1 transcript levels at diagnosis often have a worse prognosis.
  • Long-Term Outlook: Patients who achieve and maintain deep molecular remission (undetectable or very low BCR-ABL1 transcript levels) have a significantly better long-term prognosis. Conversely, those with persistent high transcript levels may be at higher risk of disease progression.

3. Treatment Decision-Making:

  • Therapeutic Selection: BCR-ABL1 testing results guide treatment decisions. Tyrosine kinase inhibitors (TKIs) are the standard therapy for CML, and the choice of TKI and dosage often depends on BCR-ABL1 transcript levels.
  • Treatment Monitoring: The test is used for ongoing monitoring of response to therapy. Regular BCR-ABL1 testing helps assess treatment efficacy and the need for therapy adjustments.
  • Early Intervention: Rising BCR-ABL1 transcript levels during therapy may indicate the need for treatment modification or intervention to prevent disease progression.

4. Treatment Endpoint:

  • Molecular Remission: The goal of therapy in CML is often to achieve and maintain deep molecular remission, which means reducing or eliminating the BCR-ABL1 transcripts to very low or undetectable levels. BCR-ABL1 testing is used to confirm when this level of response has been achieved.

5. Monitoring for Relapse:

  • Relapse Detection: BCR-ABL1 testing is crucial for detecting relapse in patients who have previously achieved remission. Rising transcript levels can be an early sign of relapse, allowing for prompt intervention.

6. Research and Clinical Trials:

  • Targeted Therapies: Research studies and clinical trials often use BCR-ABL1 testing as a primary endpoint to evaluate the efficacy of new targeted therapies for CML and Ph-positive ALL.

7. Personalized Medicine:

  • BCR-ABL1 testing enables personalized treatment approaches, tailoring therapy to the individual patient’s response and risk profile.

Keynotes

Here are key points and highlights about the BCR-ABL1 genetic test:

  1. Purpose: The BCR-ABL1 genetic test is used to detect the presence of the BCR-ABL1 fusion gene or its transcripts in the blood or bone marrow. This fusion gene is associated with certain types of leukemia.
  2. Diagnostic Utility:
    • It is a critical tool for confirming the diagnosis of chronic myeloid leukemia (CML) and a subset of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-positive ALL (Ph-positive ALL).
    • The presence of the BCR-ABL1 fusion gene is a hallmark of these diseases.
  3. Prognostic Indicator:
    • The test provides information about the level of BCR-ABL1 transcripts, which is used for risk stratification and prognosis.
    • Patients with higher transcript levels at diagnosis often have a worse prognosis.
  4. Treatment Selection:
    • BCR-ABL1 testing results guide treatment decisions. Tyrosine kinase inhibitors (TKIs) are the primary therapy for CML and Ph-positive ALL, and the choice of TKI and dosage often depends on BCR-ABL1 transcript levels.
  5. Treatment Monitoring:
    • The test is used for ongoing monitoring of treatment response. It helps assess the efficacy of therapy and the need for adjustments.
  6. Response Assessment:
    • The goal of therapy in CML is to achieve and maintain deep molecular remission, indicated by very low or undetectable BCR-ABL1 transcript levels.
  7. Relapse Detection:
    • Rising BCR-ABL1 transcript levels during therapy may indicate the need for treatment modification or intervention to prevent disease progression or relapse.
  8. Research and Clinical Trials:
    • BCR-ABL1 testing is a key endpoint in research studies and clinical trials evaluating new therapies for CML and Ph-positive ALL.
  9. Personalized Medicine:
    • The test enables personalized treatment approaches, tailoring therapy to the individual patient’s response and risk profile.
  10. Philadelphia Chromosome:
    • The BCR-ABL1 fusion gene results from a translocation between chromosomes 9 and 22, known as the Philadelphia chromosome (Ph chromosome).
  11. Test Methods:
    • BCR-ABL1 testing is typically performed using molecular techniques such as PCR or RT-qPCR to quantitate BCR-ABL1 transcripts.
  12. Monitoring Molecular Remission:
    • Achieving and maintaining deep molecular remission (low or undetectable BCR-ABL1 transcripts) is a key treatment goal in CML.
  13. Relapse Prevention:
    • The test is crucial for early detection of relapse, allowing for timely intervention to prevent disease progression.
  14. Long-Term Disease Management:
    • Regular BCR-ABL1 testing is essential for long-term management of leukemia patients, ensuring that treatment remains effective.

Further Readings

Books:

  1. “Chronic Myeloid Leukemia: A Handbook for Hematology and Oncology Practitioners” by Elias Jabbour and Jorge Cortes
    • This book offers comprehensive information on chronic myeloid leukemia (CML), including discussions of the BCR-ABL1 genetic test and its role in diagnosis and treatment.

Scientific Journals and Articles:

  1. Blood:
    • The journal Blood publishes research articles, reviews, and clinical studies related to hematological malignancies, including CML and BCR-ABL1 testing.
    • Website: Blood Journal
  2. Leukemia:
    • Leukemia is a specialized journal that covers various aspects of leukemia research, including molecular genetics and diagnostic techniques like BCR-ABL1 testing.
    • Website: Leukemia Journal
  3. Journal of Clinical Oncology:
    • This journal often features clinical studies and guidelines related to leukemia diagnosis, treatment, and monitoring, including the use of the BCR-ABL1 test.
    • Website: Journal of Clinical Oncology

Websites:

  1. American Cancer Society – Chronic Myeloid Leukemia (CML):
    • The American Cancer Society provides information on CML, including details about diagnosis, treatment, and genetic testing.
    • Website: CML Information
  2. Leukemia & Lymphoma Society (LLS) – Chronic Myeloid Leukemia (CML):
    • LLS offers resources and information about CML, including genetic testing, treatment options, and patient support.
    • Website: LLS CML Information
  3. National Cancer Institute (NCI) – Chronic Myeloid Leukemia (CML):
    • NCI provides detailed information about CML, including its genetic basis and diagnostic approaches.
    • Website: NCI CML Information
  4. Patient Advocacy Groups:
    • Organizations such as the CML Advocates Network and the CML Support Group provide valuable information and support for individuals living with CML and undergoing BCR-ABL1 testing.

Read Also...

Leave a Comment